Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992650 | 0.90 | NPC1 (0.45) | GRM5ACKR3L3MBTL1NPC1TP53 | |
| SCHEMBL990862 | 0.90 | NPC1 (0.45) | GRM5ACKR3L3MBTL1NPC1TP53 | |
| SCHEMBL990906 | 0.89 | GRM5 (0.46) | GRM5 | |
| SCHEMBL4880266 | 0.82 | GRM5 (0.53) | GRM5CHRM5NPC1RAB9AKMT2A | |
| SCHEMBL990045 | 0.81 | GRM5 (0.54) | GRM5 | |
| SCHEMBL990246 | 0.79 | GRM5 (0.58) | GRM5 | |
| SCHEMBL990781 | 0.79 | ALDH1A1 (0.48) | GRM5CHRM5L3MBTL1KMT2A | |
| SCHEMBL990810 | 0.79 | ALDH1A1 (0.48) | GRM5CHRM5L3MBTL1KMT2A | |
| SCHEMBL990768 | 0.78 | GRM5 (0.47) | GRM5CHRM5L3MBTL1 | |
| SCHEMBL990890 | 0.78 | GRM5 (0.47) | GRM5CHRM5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |